ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma.Journal of surgical oncology · 2018Pooled it
- Investigational Approaches in Treatment of Nonadvanced Mastocytosis.Current allergy and asthma reports · 2026Review
- Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain-Barré syndrome.Orphanet journal of rare diseases · 2025Article
- An Overview of Chronic Spontaneous Urticaria: Diagnosis, Management, and Treatment.Allergy, asthma & immunology research · 2025Review
- Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways.Immunological reviews · 2024Review
- Mast Cells and Resistance to Immunotherapy in Cancer.Archivum immunologiae et therapiae experimentalis · 2023Review
- Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study.Allergy · 2022Article
- KIT as a master regulator of the mast cell lineage.The Journal of allergy and clinical immunology · 2022Review
- Dependence receptors: new targets for cancer therapy.EMBO molecular medicine · 2021Review
- Steering Mast Cells or Their Mediators as a Prospective Novel Therapeutic Approach for the Treatment of Hematological Malignancies.Frontiers in oncology · 2021Review
- Improving human cancer therapy through the evaluation of pet dogs.Nature reviews. Cancer · 2020Review
- Emerging therapeutic targets for neuroblastoma.Expert opinion on therapeutic targets · 2020Review
- Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View.Cancers · 2019Review
- Canine Cancer: Strategies in Experimental Therapeutics.Frontiers in oncology · 2019Review
- CD117 (c-Kit) Is Expressed During CD8Frontiers in immunology · 2019Article
- Neuroblastoma Origin and Therapeutic Targets for Immunotherapy.Journal of immunology research · 2018Review
- Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.